Market Access: Finding Balance Amid Radical Change
Globally, the state of pharma could be described as a maelstrom. Healthcare systems are buffeted by the soaring incidence of health threats and an aging population, while costs are escalating, and government and corporate strategies have yet to be harmonized. The challenges lie in securing an agenda to enable the corporate sector and governments to grow together to bring the best outcome for patients.
Key themes covered in this whitepaper include:
- Right policy, right problem
- Legal battles, pricing, and affordability
- Patient centricity, equity, and meaningful value
- Collaboration, partnerships, and innovation
Featuring industry contributors:
- Ricardo Marek, President Europe & Canada, Takeda Pharmaceuticals
- Christoph Glaetzer, Chief Global Value and Access, Johnson & Johnson Innovative Medicine
- Andy Powrie-Smith, Executive Director, Communications & Partnerships, EFPIA